Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) ...

Proponents of a greatest-hits menu will say it's diversity on a plate, but I don't buy it. To me, the popular and familiar ...

Novo Nordisk's shares saw an uptick following the FDA's approval of Wegovy, its flagship drug, to treat a severe fatty liver disease.

Shares in Novo Nordisk rose as much as 5% in early European trading Monday, regaining some ground after losing more than half of their value over the past year.

Bobby catches some of the buzziest newcomers hitting the fringe with their first hours. Three much needed fresh voices and a ...